Oxford BioDynamics PLC Grant of Indian patent for EpiSwitch platform (9014E)

TIDMOBD

RNS Number : 9014E

Oxford BioDynamics PLC

14 February 2018

14 February 2018

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Oxford BioDynamics announces grant of Indian patent for its proprietary technology platform, EpiSwitch(TM)

Oxford BioDynamics Plc ("OBD" or the "Company"), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, today announces the grant of a key patent in India by the Office of the Controller General of Patents Designs and Trademarks covering EpiSwitch(TM), the Company's novel technology platform.

The Indian patent, number 290615, covers OBD's proprietary EpiSwitch(TM) technology designs for high resolution discovery and monitoring of regulatory conditional chromosome conformation signatures, as part of the regulatory architecture of the genome. As a biomarker modality, chromosome conformations have been shown to deliver highly informative stratifications of complex patient phenotypes, assist in better disease understanding and target identifications, and show high concordance with complex genetic and gene expression profiles. Predictive and prognostic stratifications developed by OBD on the basis of its proprietary EpiSwitch(TM) technology already offer significant improvements in patient stratifications, de-risking of drug discovery and development, and upgraded regulatory and market protection.

This patent will further extend coverage of Oxford BioDynamics' proprietary technology platform, EpiSwitch(TM), into the increasingly important Indian market. Counterparts to this patent have already been granted in the USA, Europe, China, Japan, Australia, Hong Kong, New Zealand, Singapore and South Africa.

Christian Hoyer Millar, CEO of Oxford BioDynamics, commented:

"We are delighted to announce the grant of this patent covering the use of EpiSwitch(TM) in this growing market. The grant of this patent in India further strengthens our global intellectual property portfolio as we position the Company for future growth. We believe EpiSwitch(TM) is a valuable and leading industry solution capable of characterising structural modifications to genome architecture that have a profound effect on health."

-ENDS-

For further details please contact:

 
 Oxford BioDynamics Plc          [phone] 
 Christian Hoyer Millar, 
  CEO 
 Paul Stockdale, CFO 
 
 Shore Capital                   [phone] 
 Broker and Nominated Adviser 
 Stephane Auton 
  Edward Mansfield 
 
 FTI Consulting                  [phone] 
 Financial Public Relations 
  Adviser 
 Brett Pollard 
 Natalie Garland-Collins 
 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, EpiSwitch(TM), aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch(TM) can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re--positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCSFUFDLFASESE

(END) Dow Jones Newswires

February 14, 2018 08:11 ET (13:11 GMT)